지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.12
- 수록면
- 108 - 115 (8page)
이용수
초록· 키워드
오류제보하기
Purpose: This study aimed to compare the results of treatment with adjuvant trastuzumab for 9 months versus 12 months in human epidermal growth factor 2 (HER2)-positive breast cancer patients. The primary endpoint was disease-free survival. Secondary endpoints included cardiac safety, tolerability, and overall survival.
Methods: The study included 60 non-metastatic HER2-positive breast cancer patients. All study patients underwent surgery, received adjuvant chemotherapy, radiotherapy and hormonal therapy if indicated. Thirty patients were randomized in each group. Group I patients received adjuvant trastuzumab for 12 months, while group II patients received adjuvant trastuzumab for 9 months. Patients were assessed by clinical examination and Echocardiography during treatment.
Results: After median follow-up of 12 months, 90% of the patients in group I were disease free and 83.3% of patients in group II were disease free (P=0.402). All studied population in both groups I and II were alive at the end of the 1-year follow-up period after the completion of adjuvant trastuzumab treatment thus overall survival is 100%.
Conclusion: Trastuzumab is tolerable and its side effects are reversible. Nine months of adjuvant trastuzumab treatment is more cost effective than the standard 12 months.
Methods: The study included 60 non-metastatic HER2-positive breast cancer patients. All study patients underwent surgery, received adjuvant chemotherapy, radiotherapy and hormonal therapy if indicated. Thirty patients were randomized in each group. Group I patients received adjuvant trastuzumab for 12 months, while group II patients received adjuvant trastuzumab for 9 months. Patients were assessed by clinical examination and Echocardiography during treatment.
Results: After median follow-up of 12 months, 90% of the patients in group I were disease free and 83.3% of patients in group II were disease free (P=0.402). All studied population in both groups I and II were alive at the end of the 1-year follow-up period after the completion of adjuvant trastuzumab treatment thus overall survival is 100%.
Conclusion: Trastuzumab is tolerable and its side effects are reversible. Nine months of adjuvant trastuzumab treatment is more cost effective than the standard 12 months.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (29)
참고문헌 신청
[단행본] - Morrow M / 2015 / Cancer principles & practice of oncology / Wolters Kluwer Health : 1117 ~ 1156
[인터넷자원] - Ferlay J / / GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide:IARC Cancer Base No. 10
[학술지(정기간행물)] - Ibrahim AS / 2014 / Cancer incidence in Egypt: results of the national population-based cancer registry program / J Cancer Epidemiol 2014 : 437971 ~
[학술지(정기간행물)] - Zeeneldin AA / 2013 / Clinico-pathological features of breast carcinoma in elderly Egyptian patients: a comparison with the non-elderly using population-based data / J Egypt Natl Canc Inst 25 : 5 ~ 11
[인터넷자원] - Esserman LJ / / Clinical features, diagnosis, and staging of newly diagnosed breast cancer
[인터넷자원] - Ferlay J / / GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide:IARC Cancer Base No. 10
[학술지(정기간행물)] - Ibrahim AS / 2014 / Cancer incidence in Egypt: results of the national population-based cancer registry program / J Cancer Epidemiol 2014 : 437971 ~
[학술지(정기간행물)] - Zeeneldin AA / 2013 / Clinico-pathological features of breast carcinoma in elderly Egyptian patients: a comparison with the non-elderly using population-based data / J Egypt Natl Canc Inst 25 : 5 ~ 11
[인터넷자원] - Esserman LJ / / Clinical features, diagnosis, and staging of newly diagnosed breast cancer
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage Ⅲ colon cancer
Annals of Surgical Treatment and Research
2015 .08
-
Patients with HER2-positive Early Breast Cancer Receiving Adjuvant Trastuzumab: Clinicopathological Features, Efficacy, and Factors Affecting Survival
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size
Journal of Breast Cancer
2020 .01
-
Adjuvant chemotherapy for patients with stage II high-risk and III colon cancer: Hindering factors to adherence and impact on long-term survival
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2021 .06
-
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
Cancer Research and Treatment
2016 .01
-
The Role of Adjuvant Therapy Following Surgical Resection of Small Cell Lung Cancer: A Multi-Center Study
Cancer Research and Treatment
2023 .01
-
Comparison of the Beneficial Effects of Adjuvant Chemotherapy among Young and Old Aged Breast Cancer Patients
Journal of Breast Disease
2019 .01
-
Benefits of Adjuvant Trastuzumab in HER2-Positive Breast Cancer with pT1a-bN0M0 : A Systematic Review and Meta-Analysis of Published literatures
대한외과학회 학술대회 초록집
2018 .11
-
70세 이상의 노인 대장암 환자의 수술 후 보조요법의 위험 인자와 효과
Annals of geriatric medicine and research
2015 .01
-
Adjuvant Chemotherapy and Prognostic Factors in Stage II Colon Cancer - Izmir Oncology Group Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Lack of Prognostic Impact of Adjuvant Radiation on Oncologic Outcomes in Elderly Women with Breast Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Role of Adjuvant Radiotherapy in Gastric Cancer
Journal of Gastric Cancer
2023 .01
-
보조적 항암요법을 받는 유방암 환자의 증상 경험 및 삶의 질의 변화
Asian Oncology Nursing
2015 .06
-
Adjuvant Chemotherapy
대한외과학회 학술대회 초록집
2021 .11
-
Adjuvant chemotherapy in patients with stage II colon cancer
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .12
-
Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer
Journal of Breast Cancer
2015 .01
-
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
Cancer Research and Treatment
2016 .01
-
췌장암 환자의 보조요법의 항암 치료제 결정을 위한 접근
대한내과학회지
2020 .10
-
Role of adjuvant therapy in resected periampullary adenocarcinoma: A propensity matched case-control study
Annals of Hepato-Biliary-Pancreatic Surgery
2024 .08
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2019-514-000326812